Nebula Research & Development’s Eli Lilly LLY Stock Holding History

Nebula Research & Development’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-961	Closed	-$749K	–	489
2025 Q2	$749K	Buy	+961	New	+$747K	0.06%	506
2025 Q1	–	Sell	-4,097	Closed	-$3.16M	–	1056
2024 Q4	$3.16M	Buy	4,097 +1,638	+67%	+$1.36M	0.37%	35
2024 Q3	$2.18M	Buy	+2,459	New	+$2.21M	0.26%	84
2024 Q1	–	Sell	-2,621	Closed	-$1.53M	–	873
2023 Q4	$1.53M	Buy	2,621 +1,821	+228%	+$1.06M	0.46%	24
2023 Q3	$430K	Buy	+800	New	+$412K	0.23%	165
2023 Q2	–	Sell	-869	Closed	-$298K	–	399
2023 Q1	$298K	Buy	+869	New	+$293K	0.53%	109

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nebula Research & Development's LLY Position: Q3 2025 in Review

Nebula Research & Development sold out of Eli Lilly (LLY) in Q3 2025, closing a stake of 961 shares — an estimated $749K sold.

Nebula Research & Development first reported a position in LLY in Q1 2023 and held it in 6 quarters. The position peaked at $3.16M in Q4 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.

Nebula Research & Development reported no remaining Eli Lilly position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 961 Eli Lilly shares in Q3 2025, an estimated $749K.
Nebula Research & Development first reported a position in Eli Lilly in Q1 2023 and held it in 6 quarters.
Nebula Research & Development's Eli Lilly position peaked at $3.16M in Q4 2024.
3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.